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LETTERS TO THE EDITOR 
Therapeutic Approach to Microvascular 
Angina (Syndrome X) 
I read with interest the study by Kaski et al. (1) on the use of enalapril 
in syndrome X. The therapeutic approach to this condition continues 
to focus on vasodilator agents despite previous reports of limited 
efficacy (2). Metabolic studies (3) have provided evidence of systemic 
insulin resistance inpatients with syndrome X. Myocardial metabolism 
in animal models of insulin resistance is characterized by increased 
cellular oxidation of fatty acids and markedly impaired oxidative 
glucose metabolism (4). This pattern of myocardial energy metabolism 
has also been demonstrated in patients with syndrome X (5) and 
suggests an alternative therapeutic approach to the condition. Inhibi- 
tion of fatty acid oxidation with carnitine palmitoyl transferase inhib- 
itors normalizes myocardial carbohydrate and fatty acid metabolism in
animal models of insulin resistance (4). Furthermore, carnitine palmi- 
toyl transferase inhibitors are nontoxic in vivo and have undergone 
trials as hypoglycemic agents in humans (6). 
Carnitine palmitoyl transferase inhibitors will be beneficial in 
syndrome X if the clinical manifestations of the condition result from 
the abnormal myocardial metabolism associated with insulin resis- 
tance. Certainly, exertional muscle pain is a recognized feature of 
metabolic myopathies. In addition, the occurrence of apparent isch- 
emic electrocardiographic changes is well documented in intramyocar- 
dial metabolic disturbances (7). The generalized abnormalities of 
vascular smooth muscle function characteristic of syndrome X have 
been demonstrated in both insulin-resistant and insulin-deficient states 
in humans (8). Both of these conditions are associated with increased 
cellular oxidation of fatty acids and impaired oxidative glucose metab- 
olism. Experimental studies (9) indicate that normal cellular glucose 
oxidation may be important for endothelium-dependent vascular 
smooth muscle relaxation. Hence, it is at least conceivable that the 
clinical manifestations of syndrome X result from the deranged ener~' 
metabolism associated with insulin resistance and could, therefore, be 
altered by carnitine palmitoyl transferase inhibitors. On the basis of 
the available vidence a trial of metabolic therapy in syndrome X 
appears to be justified. 
JOHN P. SEERY, MRCP 
Department ofMedicine 
Ealing Hospital NHS Trust 
Uxbridge Road 
SouthaU, Middlesex UB1 3HI$~ England. United Kingdom 
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Reply 
I am grateful to Seery for his interesting comments. I share Seery's 
concern that the therapeutic approach to the so-called cardiac syn- 
drome X has focused mainly on antianginal gents, whether vasodila- 
tots or otherwise. However, there are reasons for this. An ischemic 
origin for syndrome X has been postulated in view of the anginal 
character of the chest pain, ST segment depression on exercise testing 
and findings of "objective" evidence for myocardial ischemia and 
reduced coronary blood flow reserve in some patients (1). Studies by 
Cannon et al. (2) further confirmed that patients with angina and 
normal coronary arteriographic findings had transient myocardial 
ischemia, as assessed by transmyocardial l ctate measurements and 
radionuclide ventriculography. In the absence of epicardial narrow- 
ings, prearteriolar microvascular dysfunction was postulated as the 
mechanism responsible for ischemia in this condition ("microvascular 
angina") (2). Recently, both microvascular endothelial dysfunction 
and ischemia were documented by Egashira et al. (3) in patients with 
syndrome X. However, despite evidence of myocardial ischemia in 
some patients, controversy exists as to the true nature of syndrome X. 
Indeed, abnormal coronary blood flow reserve and myocardial isch- 
emia can be objectively demonstrated in only a minority of patients 
with angina and normal coronary arteries (4). Other hypotheses have 
therefore been postulated; among these are abnormal pain perception, 
increased sympathetic activity and metabolic abnormalities. Studies 
have now focused on these mechanisms, and it has been shown (5) thal 
imipramine, a drug that has been used successfully in the managemen! 
of chronic pain syndromes, improved the symptoms of patients with 
chest pain and normal coronary arteriographic results. We recent b 
observed (6) that patients with syndrome X have impaired autonomic: 
function on the basis of reduced heart rate variability. Relevant o this 
observation, and to the effects of enalapril n patients with syndrome 
(7), is the fact that angiotensin II facilitates ympathetic nerve influ-- 
ences in the heart. Treatment with angiotensin-converting e zyme 
inhibitors is known to attenuate sympathetically mediated coronary 
vasoconstriction (7), and this could explain the beneficial effects o1! 
enalapril in our patients with syndrome X and microvascular ngina. 
Increased sympathetic drive is certainly an attractive pathogenetic 
hypothesis in the setting of angina with normal findings on the 
coronary arteriogram. Interaction between the central and sympathetic 
nervous systems may influence pain perception (4), and increased 
sympathetic drive is present in patients with insulin resistance, recently 
described in association with syndrome X (8). 
I agree with Seery that carnitine palmitoyl transferase inhibitors 
could be beneficial in patients with syndrome X for the reasons 
expressed in his letter. However, it would be erroneous to assume, a's 
Seery appears to do, that cardiac syndrome X is caused by abnormal 
cardiac metabolism due to insulin resistance, and, therefore, that 
interventions aimed at improving this metabolic abnormality will be 
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universally beneficial for patients with this syndrome. We ought to 
remember that the term "syndrome X" is a descriptive t rm only, and 
a poor one indeed. Syndrome X is a heterogeneous entity, and 
different patient subgroups have now been identified. In some patients, 
symptoms may be caused by myocardial ischemia or microvascular 
endothelial dysfunction, or both; in others by increased pain percep- 
tion, estrogen deficiency, psychologic disturbances or a combination of 
these. Patients with insulin resistance may represent another pathoge- 
netic subgroup. However, the proportion of patients with syndrome X
in whom insulin resistance isresponsible for the clinical manifestations 
is not yet known. 
A trial of metabolic therapy, as suggested by Seery, may be 
justifiable in syndrome X. However, this approach is likely to succeed 
in only those patients whose symptoms are caused by the metabolic 
disorder but not in every patient with angina and normal coronary 
arteriographic findings. Too often since the initial description of 
syndrome X have investigators mistakingly attempted to identify a 
single etiologic mechanism for this heterogeneous condition. Let us 
not fall into this trap yet again. 
JUAN CARLOS KASKI, MD, FACC, FESC 
Coronary Artery Disease Research Group 
St. George's Hospital Medical School 
Cranmer Terrace 
London SWI7 ORE, England, United Kingdom 
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Assessment of Cardiovascular 
Autonomic Function 
I read the report by Zarich et al. (1) with immense interest. However, 
I am concerned about the methodology, used in testing the autonomic 
function of their patients. The cutoff points for an "abnormal" test 
result for the Valsalva maneuver and the systolic blood pressure 
response to standing were taken as 1.25 and 20 mm Hg, respectively. In 
fact, these should be 1.10 for the Valsalva maneuver and 30 mm Hg for 
a decrease in systolic blood pressure (2). Zarich et al. did not take into 
consideration the heart rate response to standing, which tests the 
parasympathetic autonomic nervous ystem. The involvement of the 
parasympathetic autonomic nervous ystem is inferred by Zarich et al. 
to be more involved in diabetic autonomic neuropathy, causing the 
circadian pattern of myocardial isehemia. Again, the autonomic score 
is given as 0, 1 or 2, depending on whether a test result is normal, 
borderline or abnormal (3). A "battery" of at least five autonomic tests 
should be performed rather than the four used by Zarich et al. because 
no single test is sensitive enough to detect and classify types of 
autonomic dysfunction (3). Despite the battery of five autonomic tests, 
-6% of patients with autonomic insufficiency are unclassifiable and 
are grouped as "atypical" (2,3). I note that the Valsalva maneuver was 
performed only once, whereas a mean of three successive maneuvers i  
recommended (4). Such tests would stratify patients differently, and 
the differences in circadian patterns of ambulatory myocardial isch- 
emia between groups I and II in the Zarich et al. study might therefore 
not hold true. 
The frequency of silent myocardial ischemia in patients with 
autonomic insufficiency may be explained by a higher pain sensitivity 
threshold and ischemia tolerance in diabetic patients with autonomic 
neuropathy (5,6). In experimental nimals, a "denervation supersen- 
sitivity," causing enhanced sensitivity to the action of the sympathetic 
nervous ystem may occur (7). Pericardial prostaglandins released in 
the pericardial fluid, modulating the sympathetic effects of the heart, is 
an interesting hypothesis (7). Myocardial ischemia s the cause rather 
than the effect of neuropathy, including autonomic neuropathy, par- 
ticularly in early myocardial ischemia, is an exciting new concept and 
requires further confirmation (8,9). 
MUMTAZ A. SIDDIQUI, MD, MRCP 
The Graduate Hospital 
Philadelphia, Pennsylvania 19146 
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Reply 
Siddiqui asserts that there is one battery of cardiovascular tests of the 
autonomic nervous ystem with universally accepted cutoffs between 
normal and abnormal test results. In reality, there are a number of 
different ests assessing cardiovascular utonomic function and no 
single established battery (1-3). Any test used to assess cardiovascular 
autonomic function should have acceptable sensitivity, specificity and 
reproducibility. Some investigators (2-4) have reported, for example, 
that the heart rate response to standing, a test advocated by Siddiqui, 
does not fulfill these criteria. The four tests that we used in our study 
to measure autonomic function satisfy the sensitivity, specificity and 
